<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mimmun</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская иммунология</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Immunology (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1563-0625</issn><issn pub-type="epub">2313-741X</issn><publisher><publisher-name>SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15789/1563-0625-AOT-2690</article-id><article-id custom-type="elpub" pub-id-type="custom">mimmun-2989</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Сопряженность клеточной дифференцировки опухоли с цитокинпродуцирующим резервом при люминальных и нелюминальных подтипах рака молочной железы</article-title><trans-title-group xml:lang="en"><trans-title>Association of tumor cell differentiation with cytokine-producing reserve in luminal and nonluminal subtypes of breast cancer</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мангазеева</surname><given-names>Е. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Mangazeeva</surname><given-names>E. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мангазеева Екатерина Дмитриевна - младший научный сотрудник центральной научно-исследовательской лаборатории</p><p>630091, г. Новосибирск, Красный пр., 52</p><p>Тел./факс: 8 (383) 226-35-60</p></bio><bio xml:lang="en"><p>Ekaterina D. Mangazeeva, Research Associate, Central Research Laboratory</p><p>52 Krasnyy Ave Novosibirsk 630091</p><p>Phone/fax: +7 (383) 226-35-60</p></bio><email xlink:type="simple">lpciip@211.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Студеникина</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Studenikina</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Студеникина А.А. – к.м.н., научный сотрудник центральной научно-исследовательской лаборатории; научный сотрудник</p><p>г. Новосибирск</p></bio><bio xml:lang="en"><p>Studenikina A.A., PhD (Medicine), Research Associate, Central Research Laboratory; Research Associate</p><p>Novosibirsk</p></bio><email xlink:type="simple">lpciip@211.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-3169-3747</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рыжикова</surname><given-names>С. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Ryzhikova</surname><given-names>S. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Рыжикова С.Л. – начальник лаборатории</p><p>г. Новосибирск</p></bio><bio xml:lang="en"><p>Ryzhikova S.L., Head of Laboratory</p><p>Novosibirsk</p></bio><email xlink:type="simple">ryzhikova@vector-best.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7180-010X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Аутеншлюс</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Autenshlyus</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Аутеншлюс А.И. – д.б.н., профессор, заведующий центральной научно-исследовательской лабораторией; главный научный сотрудник</p><p>г. Новосибирск</p></bio><bio xml:lang="en"><p>Autenshlyus A.I., PhD, MD (Biology), Professor, Head, Central Research Laboratory; Chief Research Associate, Institute of Molecular Biology and Biophysics</p><p>Novosibirsk</p></bio><email xlink:type="simple">lpciip@211.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Новосибирский государственный медицинский университет»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Novosibirsk State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Новосибирский государственный медицинский университет»; Научно-исследовательский институт молекулярной биологии и биофизики ФГБНУ «Федеральный исследовательский центр фундаментальной и трансляционной медицины»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Novosibirsk State Medical University; Institute of Molecular Biology and Biophysics, Federal Research Center of Fundamental and Translational Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>АО «Вектор-Бест»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Vector-Best JSC</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>08</day><month>01</month><year>2025</year></pub-date><volume>27</volume><issue>1</issue><fpage>97</fpage><lpage>106</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мангазеева Е.Д., Студеникина А.А., Рыжикова С.Л., Аутеншлюс А.И., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Мангазеева Е.Д., Студеникина А.А., Рыжикова С.Л., Аутеншлюс А.И.</copyright-holder><copyright-holder xml:lang="en">Mangazeeva E.D., Studenikina A.A., Ryzhikova S.L., Autenshlyus A.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mimmun.ru/mimmun/article/view/2989">https://www.mimmun.ru/mimmun/article/view/2989</self-uri><abstract><p>Существует прямая взаимосвязь между выраженностью функционального, морфологического и биохимического атипизма клеток опухоли и степенью ее злокачественности. Выделяют пять молекулярно-генетических подтипов рака молочной железы. При этом известно, что наиболее агрессивным течением характеризуются нелюминальные подтипы, в особенности – тройной негативный рак молочной железы. Целью работы явилось определение сопряженности между относительным содержанием клеток различной степени дифференцировки с продукцией цитокинов биоптатами рака молочной железы при люминальных и нелюминальных подтипах рака молочной железы. Материалом исследования служили биоптаты 49 женщин с инвазивной карциномой молочной железы неспецифического типа, средний возраст которых составил 59 лет. Пациенты были разделены на три группы в зависимости от принадлежности к тому или иному молекулярно-генетическому подтипу опухоли. В I группу включены пациенты с люминальным подтипом А, во вторую – с люминальным В и в III – с нелюминальными подтипами рака молочной железы. Изучали спонтанную и стимулированную поликлональными активаторами продукцию цитокинов. Значение цитокинпродуцирующего резерва биоптатов выражали с помощью индекса влияния поликлональных активаторов ввиду его точности, позволяющей избежать ошибки за счет одинаковых размеров биоптата каждого пациента и условий их инкубирования. Относительное содержание опухолевых клеток различной степени дифференцировки в образцах оценивали с помощью светооптической микроскопии с учетом Ноттингемской градирующей системы. При оценке спонтанной и стимулированной продукции цитокинов, а также степени дифференцировки клеток образцов опухоли выявлены прямые и обратные корреляционные связи между исследуемыми группами. Наиболее важным показателем оказался индекс влияния поликлонального активатора на продукцию биоптатами IL-10 и VEGF-А. Благодаря этому мы можем представить персонифицированные сведения по каждому пациенту по этим двум цитокинам еще до начала лечения. Анализ ROC-кривых показал хорошее качество и оптимальные значения точек отсечения концентраций цитокинов и относительного содержания низкодифференцированных клеток, которые могли бы наилучшим образом предсказать наличие неблагоприятных нелюминальных подтипов рака молочной железы. Основываясь на полученных нами данных, можно сделать вывод о том, что цитокинпродуцирующий резерв сопряжен с клеточной дифференцировкой и зависит от молекулярно-генетического подтипа опухоли.</p></abstract><trans-abstract xml:lang="en"><p>There is a direct association between the functional, morphologic and biochemical atypic features of cellular tumor expression and malignancy. Five molecular-genetic subtypes of breast cancer are recognized. The most aggressive course is known to be characterized by non-luminal subtypes, in particular, a triplenegative breast cancer. The aim of this research is to determine the association between the percentage of the cells showing distinct differentiation types, and cytokine production by breast cancer bioptates in both luminal and non-luminal breast cancer subtypes. Bioptates of 49 women with the invasive breast carcinoma of nonspecific type, at the average age of 59 years, were used as the material for the study. The patients were divided into three groups according to the molecular-genetic subtype of cancer. Group I included patients with luminal subtype A, group II – with luminal B and group III – with non-luminal subtypes of breast cancer. Spontaneous and in vitro stimulated by polyclonal activators production of cytokines was evaluated. The level of cytokineproducing reserve by the biopsy specimens was expressed as the influence index of polyclonal activators, due to its accuracy, thus making it possible to avoid errors due to the similar sizes of bioptates from each patient and their incubation conditions. The percentage of tumor cells of varying degrees of differentiation in the samples was assessed using light microscopy by means of the Nottingham grading system. When assessing spontaneous and stimulated production of cytokines, as well as degree of cell differentiation of tumor samples, direct and reverse correlations were revealed between the study groups. The most important parameter was the influence index of the polyclonal activator which characterized production of IL-10 and VEGF-A by the bioptates. Therefore, we can provide personalized information for each patient, in particular, for these two cytokines, even before starting the treatment.The analysis of ROC-curves showed good quality and optimal level of cytokine concentration and percentage of low-differentiated cells. This approach could predict the presence of unfavorable non-luminal breast cancer subtypes in the best way. In general, we can make a conclusion that cytokine-producing reserve is connected with cellular differentiation and depends on molecular-genetic subtype of the tumor.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>рак молочной железы</kwd><kwd>биоптаты</kwd><kwd>цитокины</kwd><kwd>молекулярно-генетические подтипы</kwd><kwd>клеточная дифференцировка</kwd><kwd>поликлональный активатор.</kwd></kwd-group><kwd-group xml:lang="en"><kwd>breast cancer</kwd><kwd>tumor biopsies</kwd><kwd>cytokines</kwd><kwd>molecular subtypes</kwd><kwd>cell differentiation</kwd><kwd>polyclonal activator</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Аутеншлюс А.И., Архипов С.А., Михайлова Е.С., Архипова В.В., Вараксин Н.А. Сопряженность цитокинового профиля супернатанта инвазивной карциномы молочной железы с ее молекулярными и гистопатологическими характеристиками// Сибирский онкологический журнал. – 2023. - Т. 22, №6. - С. 92–102. [Autenshlyus A.I., Arkhipov S.A., Mikhaylova E.S., Arkhipova V.V., Varaksin N.A. Relationship between the cytokine profile of supernatants of invasive breast carcinoma and its molecular and histopathological characteristics. Sibirskij onkologičeskij žurnal, 2023, Vol. 22, no. 6, pp. 92-102.]</mixed-citation><mixed-citation xml:lang="en">Аутеншлюс А.И., Архипов С.А., Михайлова Е.С., Архипова В.В., Вараксин Н.А. Сопряженность цитокинового профиля супернатанта инвазивной карциномы молочной железы с ее молекулярными и гистопатологическими характеристиками// Сибирский онкологический журнал. – 2023. - Т. 22, №6. - С. 92–102. [Autenshlyus A.I., Arkhipov S.A., Mikhaylova E.S., Arkhipova V.V., Varaksin N.A. Relationship between the cytokine profile of supernatants of invasive breast carcinoma and its molecular and histopathological characteristics. Sibirskij onkologičeskij žurnal, 2023, Vol. 22, no. 6, pp. 92-102.]</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Архипов С.А., Михайлова Е.С., Кунц Т.А. , Карпухина К.В., Могильная Е.Д., Соловьев К.А., Вараксин Н.А., Аутеншлюс А.И. Цитокинпродуцирующий резерв иммунокомпетентных клеток крови и инвазивного протокового рака молочной железы, его взаимосвязь с патогистологическими и иммуногистохимическими параметрами злокачественного новообразования // Медицинская иммунология. – 2016. - Т. 1, № 5.- С. 459-468. [Arkhipov S.A., Mikhailova E.S., Kunts T.A., Karpukhina K.V., Mogilnaya E.D., Solovyev K.A., Varaksin N.A., Autenshlyus A.I. Cytokine-producing reserve of immunocompetent cells from blood and invasive ductal breast cancer tissues: its correlation with histopathological and immunohistochemical parameters of malignant neoplasia. Med Immunology, 2016, Vol 1, no 5, pp 459-468.]</mixed-citation><mixed-citation xml:lang="en">Архипов С.А., Михайлова Е.С., Кунц Т.А. , Карпухина К.В., Могильная Е.Д., Соловьев К.А., Вараксин Н.А., Аутеншлюс А.И. Цитокинпродуцирующий резерв иммунокомпетентных клеток крови и инвазивного протокового рака молочной железы, его взаимосвязь с патогистологическими и иммуногистохимическими параметрами злокачественного новообразования // Медицинская иммунология. – 2016. - Т. 1, № 5.- С. 459-468. [Arkhipov S.A., Mikhailova E.S., Kunts T.A., Karpukhina K.V., Mogilnaya E.D., Solovyev K.A., Varaksin N.A., Autenshlyus A.I. Cytokine-producing reserve of immunocompetent cells from blood and invasive ductal breast cancer tissues: its correlation with histopathological and immunohistochemical parameters of malignant neoplasia. Med Immunology, 2016, Vol 1, no 5, pp 459-468.]</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Пауков В. С. Клиническая патология. – М.:Литтерра, 2018. – 768 с. [Paukov V.S. Clinical pathology. Moscow: Littera, 2018,768 p.]</mixed-citation><mixed-citation xml:lang="en">Пауков В. С. Клиническая патология. – М.:Литтерра, 2018. – 768 с. [Paukov V.S. Clinical pathology. Moscow: Littera, 2018,768 p.]</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Поспехова Н.И., Головина Д.А., Филиппова М.Г., Семьянихина А.В., Дранко С.Л., Данишевич А.М., Строганова А.М. Молекулярно-биологические подтипы рака молочной железы у носителей мутаций в гене BRCA1 // Успехи молекулярной онкологии. – 2020. - Т 7, №4. - С. 29-36. [Pospekhova N.I., Golovina D.A, Filippova M.G., Semyanikhina A.V, Dranko S.L., Danishevich A.M, Stroganova A.M. Molecular biological subtypes of breast cancer in brca1 mutation carriers. Uspehi Molekulârnoj Onkologii, 2020, Vol 7, no. 4, pp 29-36]</mixed-citation><mixed-citation xml:lang="en">Поспехова Н.И., Головина Д.А., Филиппова М.Г., Семьянихина А.В., Дранко С.Л., Данишевич А.М., Строганова А.М. Молекулярно-биологические подтипы рака молочной железы у носителей мутаций в гене BRCA1 // Успехи молекулярной онкологии. – 2020. - Т 7, №4. - С. 29-36. [Pospekhova N.I., Golovina D.A, Filippova M.G., Semyanikhina A.V, Dranko S.L., Danishevich A.M, Stroganova A.M. Molecular biological subtypes of breast cancer in brca1 mutation carriers. Uspehi Molekulârnoj Onkologii, 2020, Vol 7, no. 4, pp 29-36]</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Соснина А.В., Великая Н.В., Вараксин Н.А., Гришаев М.П., Аутеншлюс А.И. Роль цитокинов в патогенезе злокачественных новообразований. – Н.: ЗАО ИПП «Офсет», 2014. – 49 с [Sosnina A.V., Velikaya N.V., Varaksin N.A., Grishaev M.P., Autenshlyus A.I. Role of cytokines in the pathogenesis of malignant neoplogms. Novosibirsk: ZAO IPP “Ofset”, 2014, 49p.]</mixed-citation><mixed-citation xml:lang="en">Соснина А.В., Великая Н.В., Вараксин Н.А., Гришаев М.П., Аутеншлюс А.И. Роль цитокинов в патогенезе злокачественных новообразований. – Н.: ЗАО ИПП «Офсет», 2014. – 49 с [Sosnina A.V., Velikaya N.V., Varaksin N.A., Grishaev M.P., Autenshlyus A.I. Role of cytokines in the pathogenesis of malignant neoplogms. Novosibirsk: ZAO IPP “Ofset”, 2014, 49p.]</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Al Kawas H., Saaid I, Jank P., Westhoff C.C., Denkert C., Pross T., Weiler K.B.S., Karsten M.M. How VEGF-A and its splice variants affect breast cancer development - clinical implications. Cell Oncol (Dordr), 2022, Vol. 45, no. 2, pp. 227-239.</mixed-citation><mixed-citation xml:lang="en">Al Kawas H., Saaid I, Jank P., Westhoff C.C., Denkert C., Pross T., Weiler K.B.S., Karsten M.M. How VEGF-A and its splice variants affect breast cancer development - clinical implications. Cell Oncol (Dordr), 2022, Vol. 45, no. 2, pp. 227-239.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Abelev G.I. Differentiation mechanisms and malignancy. Biochemistry (Mosc), 2000, Vol. 65, no. 1, pp.107-116</mixed-citation><mixed-citation xml:lang="en">Abelev G.I. Differentiation mechanisms and malignancy. Biochemistry (Mosc), 2000, Vol. 65, no. 1, pp.107-116</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Autenshlyus A., Arkhipov S., Mikhailova E., Marinkin I., Arkhipova V., Mogilnaya E., Varaksin N., Rukavishnikov M. Cytokine production in mammary adenocarcinoma and its microenvironmental cells in patients with or without metastases in regional lymph nodes. Int J Immunopathol Pharmacol, 2017, Vol. 30, no. 3, pp. 308-314.</mixed-citation><mixed-citation xml:lang="en">Autenshlyus A., Arkhipov S., Mikhailova E., Marinkin I., Arkhipova V., Mogilnaya E., Varaksin N., Rukavishnikov M. Cytokine production in mammary adenocarcinoma and its microenvironmental cells in patients with or without metastases in regional lymph nodes. Int J Immunopathol Pharmacol, 2017, Vol. 30, no. 3, pp. 308-314.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Faria S.S., Costantini S., de Lima V.C.C., de Andrade V.P., Rialland M., Cedric R., Budillon A., Magalhães K.G. NLRP3 inflammasome-mediated cytokine production and pyroptosis cell death in breast cancer. J Biomed Sci, 2021, Vol. 28, no. 1, pp. 26.</mixed-citation><mixed-citation xml:lang="en">Faria S.S., Costantini S., de Lima V.C.C., de Andrade V.P., Rialland M., Cedric R., Budillon A., Magalhães K.G. NLRP3 inflammasome-mediated cytokine production and pyroptosis cell death in breast cancer. J Biomed Sci, 2021, Vol. 28, no. 1, pp. 26.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Felcher C.M., Bogni E.S., Kordon E.C. IL-6 Cytokine Family: A Putative Target for Breast Cancer Prevention and Treatment. Int J Mol Sci, 2022, Vol. 23, no. 3, pp. 1809.</mixed-citation><mixed-citation xml:lang="en">Felcher C.M., Bogni E.S., Kordon E.C. IL-6 Cytokine Family: A Putative Target for Breast Cancer Prevention and Treatment. Int J Mol Sci, 2022, Vol. 23, no. 3, pp. 1809.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Habanjar O., Bingula R., Decombat C., Diab-Assaf M., Caldefie-Chezet F., Delort L. Crosstalk of Inflammatory Cytokines within the Breast Tumor Microenvironment. Int J Mol Sc,. 2023, Vol. 24, no. 4, pp. 4002.</mixed-citation><mixed-citation xml:lang="en">Habanjar O., Bingula R., Decombat C., Diab-Assaf M., Caldefie-Chezet F., Delort L. Crosstalk of Inflammatory Cytokines within the Breast Tumor Microenvironment. Int J Mol Sc,. 2023, Vol. 24, no. 4, pp. 4002.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Hamidullah, Changkija B., Konwar R. Role of interleukin-10 in breast cancer. Breast Cancer Res Treat, 2012, Vol. 133, no. 1, pp. 11-21.</mixed-citation><mixed-citation xml:lang="en">Hamidullah, Changkija B., Konwar R. Role of interleukin-10 in breast cancer. Breast Cancer Res Treat, 2012, Vol. 133, no. 1, pp. 11-21.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Holm-Rasmussen E.V., Jensen M.B., Balslev E., Kroman N., Tvedskov T.F. Reduced risk of axillary lymphatic spread in triple-negative breast cancer. Breast Cancer Res Treat, 2015, Vol. 149, no. 1, pp. 229-36.</mixed-citation><mixed-citation xml:lang="en">Holm-Rasmussen E.V., Jensen M.B., Balslev E., Kroman N., Tvedskov T.F. Reduced risk of axillary lymphatic spread in triple-negative breast cancer. Breast Cancer Res Treat, 2015, Vol. 149, no. 1, pp. 229-36.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Liu L., Wu Y., Zhang C., Zhou C., Li Y., Zeng Y., Zhang C., Li R., Luo D., Wang L., Zhang L., Tu S., Deng H., Luo S., Chen Y.G., Xiong X., Yan X. Cancer-associated adipocyte-derived G-CSF promotes breast cancer malignancy via Stat3 signaling. J Mol Cell Biol, 2020, Vol. 12, no. 9, pp. 723-737.</mixed-citation><mixed-citation xml:lang="en">Liu L., Wu Y., Zhang C., Zhou C., Li Y., Zeng Y., Zhang C., Li R., Luo D., Wang L., Zhang L., Tu S., Deng H., Luo S., Chen Y.G., Xiong X., Yan X. Cancer-associated adipocyte-derived G-CSF promotes breast cancer malignancy via Stat3 signaling. J Mol Cell Biol, 2020, Vol. 12, no. 9, pp. 723-737.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Mesa-Eguiagaray I., Wild S.H., Rosenberg P.S., Bird S.M., Brewster D.H., Hall P.S., Cameron D.A., Morrison D., Figueroa J.D. Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data. Br J Cancer, 2020, Vol. 123, no 5, pp. 852-859</mixed-citation><mixed-citation xml:lang="en">Mesa-Eguiagaray I., Wild S.H., Rosenberg P.S., Bird S.M., Brewster D.H., Hall P.S., Cameron D.A., Morrison D., Figueroa J.D. Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data. Br J Cancer, 2020, Vol. 123, no 5, pp. 852-859</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Mouchemore K.A., Anderson R.L., Hamilton J.A. Neutrophils, G-CSF and their contribution to breast cancer metastasis. FEBS J,. 2018, Vol. 285, no. 4, pp. 665-679.</mixed-citation><mixed-citation xml:lang="en">Mouchemore K.A., Anderson R.L., Hamilton J.A. Neutrophils, G-CSF and their contribution to breast cancer metastasis. FEBS J,. 2018, Vol. 285, no. 4, pp. 665-679.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Nielsen T.O., Jensen M.B., Burugu S., Gao D., Jørgensen C.L., Balslev E., Ejlertsen B. High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial. Clin Cancer Res, 2017,Vol. 23, no. 4, pp. 946-953</mixed-citation><mixed-citation xml:lang="en">Nielsen T.O., Jensen M.B., Burugu S., Gao D., Jørgensen C.L., Balslev E., Ejlertsen B. High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial. Clin Cancer Res, 2017,Vol. 23, no. 4, pp. 946-953</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Rakha E.A., Reis-Filho J.S., Baehner F., Dabbs D.J., Decker T., Eusebi V., Fox S.B., Ichihara S., Jacquemier J., Lakhani S.R., Palacios J., Richardson A.L., Schnitt S.J., Schmitt F.C., Tan P.H., Tse G.M., Badve S., Ellis I.O. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res., 2010, Vol. 12, no. 4, pp. 207.</mixed-citation><mixed-citation xml:lang="en">Rakha E.A., Reis-Filho J.S., Baehner F., Dabbs D.J., Decker T., Eusebi V., Fox S.B., Ichihara S., Jacquemier J., Lakhani S.R., Palacios J., Richardson A.L., Schnitt S.J., Schmitt F.C., Tan P.H., Tse G.M., Badve S., Ellis I.O. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res., 2010, Vol. 12, no. 4, pp. 207.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Smolanka I.I., Bagmut I.Y., Movchan O.V., Sheremet M.I., Bilyi O.M., Lyashenko A.O., Dosenko I.V., Loboda A.D., Ivankova O.M., Kolisnyk I.L. Features of VEGF and IL-6 expression in patients with inflammatory breast cancer considering molecular-biological characteristics. J Med Life, 2023, Vol. 16, no. 1, pp. 153-159.</mixed-citation><mixed-citation xml:lang="en">Smolanka I.I., Bagmut I.Y., Movchan O.V., Sheremet M.I., Bilyi O.M., Lyashenko A.O., Dosenko I.V., Loboda A.D., Ivankova O.M., Kolisnyk I.L. Features of VEGF and IL-6 expression in patients with inflammatory breast cancer considering molecular-biological characteristics. J Med Life, 2023, Vol. 16, no. 1, pp. 153-159.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Lønning P.E., Børresen-Dale A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A., 2001, Vol. 98, no. 19, pp. 10869-74.</mixed-citation><mixed-citation xml:lang="en">Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Lønning P.E., Børresen-Dale A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A., 2001, Vol. 98, no. 19, pp. 10869-74.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Tan C., Hu W., He Y., Zhang Y., Zhang G., Xu Y., Tang J. Cytokine-mediated therapeutic resistance in breast cancer. Cytokine, 2018, Vol. 108, pp. 151-159.</mixed-citation><mixed-citation xml:lang="en">Tan C., Hu W., He Y., Zhang Y., Zhang G., Xu Y., Tang J. Cytokine-mediated therapeutic resistance in breast cancer. Cytokine, 2018, Vol. 108, pp. 151-159.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA, 2013, Vol. 310, no. 20, pp. 2191-4.</mixed-citation><mixed-citation xml:lang="en">World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA, 2013, Vol. 310, no. 20, pp. 2191-4.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Yan R., Ren F., Li J., Rao X., Lv Z., Zheng C., Zhang F. Nuclei-Guided Network for Breast Cancer Grading in HE-Stained Pathological Images. Sensors (Basel, 2022, Vol. 22, no. 11, pp. 4061.</mixed-citation><mixed-citation xml:lang="en">Yan R., Ren F., Li J., Rao X., Lv Z., Zheng C., Zhang F. Nuclei-Guided Network for Breast Cancer Grading in HE-Stained Pathological Images. Sensors (Basel, 2022, Vol. 22, no. 11, pp. 4061.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
